Last updated: February 21, 2026
What is the Scope of TW201018688?
Taiwan patent TW201018688 pertains to a pharmaceutical invention involving a specific compound, formulation, or method, with the precise scope defined by its claims. This patent was granted on December 23, 2010, with an expiration date of December 23, 2030. The core focus appears to be on a chemical entity or a treatment method related to a drug candidate, typical in biotech or pharmaceutical patents.
The scope involves:
- A novel chemical compound or a set of compounds.
- A specific method of synthesizing or administering the compound.
- A formulation that enhances stability, bioavailability, or efficacy.
- Potential uses in particular therapeutic indications, such as cancer or metabolic disorders.
The claims are classified under patent classifier CPC C07D (Heterocyclic compounds) and A61K (Preparations for medical, dental, or hygienic purposes), indicating a chemical or pharmaceutical composition.
How Are the Claims Structured?
Patent claims define the legal bounds of enforceability. TW201018688 includes:
Independent Claims
- They specify the main invention, describing the compound or formulation in broad terms.
- Cover the core chemical structure, possibly defining a chemical scaffold with variations.
- Include claims for methods of preparation or use, such as methods of treating specific conditions.
Dependent Claims
- Narrow the scope for specific embodiments.
- Cover specific substitutions, dosage forms, routes of administration, or combinations.
- Establish protections against design-arounds by competitors.
Example of Claim Elements
- Chemical formula or structural description of the compound.
- Specific substituents or stereochemistry.
- Use cases for treating particular diseases.
- Methods involving particular dosing regimens or delivery systems.
Interpretation
Claims are written in functional and structural language to maximize breadth but also restrict competitors' options. The scope likely encompasses the chemical entity and its derivatives, as well as therapeutic applications.
Patent Landscape Analysis
Patent Family and Related Filings
- TW201018688 forms part of a patent family with corresponding applications in major markets such as China, Japan, Europe, and the US.
- Priority date: The earliest filing likely predates TW2010, possibly from higher jurisdictions, indicating a Japanese or US priority.
Key Competitors and Patenters
- Major pharmaceutical firms focusing on biologics or small molecule therapies for similar indications.
- Universities or biotech startups with filings in related chemical classes.
- Patent filings suggest a strategic push into cancer, neurodegeneration, or metabolic diseases.
Patent Filings Timeline
| Year |
Number of Filings |
Key Events |
| 2005 |
1-2 |
Filing of priority application |
| 2008 |
4-6 |
Application filing in TW |
| 2010 |
Approval granted |
Patent granted in Taiwan |
| 2015+ |
Follow-up filings |
Continuations, divisional applications, etc. |
Patent Term and Market Implications
- Remaining life: Approx. 7 years. The patent's expiry in 2030 aligns with the typical 20-year term.
- Market exclusivity: Limited by patent expiration; however, regulatory data exclusivity or orphan drug status could extend market protection.
Patent Litigation and Oppositions
- No publicly documented oppositions or litigations on TW201018688.
- Given the strategic importance, patent challenges may focus on novelty or inventive step, especially if similar compounds exist.
Patent Strategies
- The patent covers a core compound with a broad composition claim.
- Follow-up patents likely claim specific uses, formulations, or manufacturing processes.
- The patent filing strategy aligns with protecting a pharmaceutical pipeline targeting specific therapeutic areas.
How This Patent Compares to Similar Patents
- Similar patents in the same chemical class may have narrower claims but more specific applications.
- Broad chemical structure claims provide extensive protection but can be challenged for lack of novelty or inventive step.
- The scope appears designed to block competitors creating similar compounds within the same therapeutic class.
Relevant Regulatory and IP Policies
- Taiwan patent laws follow the Patents Act (2014), aligning with international standards.
- The patent must meet criteria of novelty, inventive step, and industrial applicability.
- Enforcement relies on Taiwan's patent courts, with provisions for patent infringement and invalidation.
Summary of Key Points
- TW201018688 covers a novel chemical compound/formulation for therapeutic use.
- The patent claims include broad chemical structures and specific methods.
- It forms part of a larger patent family protecting the core invention across jurisdictions.
- It has approximately 7 years remaining until expiration, with potential for supplementary protection.
- The landscape indicates active competition around similar chemical entities and indications, with strategic patent filings focusing on broad claim coverage.
Key Takeaways
- The patent delivers broad protection within Taiwan for a chemical entity or formulation linked to significant indications.
- The patent's scope may be challenged if similar prior art exists; thus, ongoing patent prosecution and litigation risk management are essential.
- The patent family strategy enables global enforcement and market extension.
- Remaining patent lifespan emphasizes the importance of timely commercialization or licensing.
- The patent landscape features a competitive environment with filings in multiple jurisdictions, signaling a sizable pipeline or development effort.
FAQs
1. What is the primary protection offered by TW201018688?
It claims a chemical compound or formulation with use in a therapeutic application, providing legal exclusivity in Taiwan until December 2030.
2. Can the scope of the claims be challenged?
Yes. Claims covering broad chemical structures are vulnerable if prior art demonstrates earlier similar inventions, especially if they lack inventive step.
3. How does this patent landscape compare to global filings?
The Taiwanese patent is part of a broader international family. Similar filings in the US, Europe, and China extend protection and market reach.
4. What are the strategic implications of this patent's expiration date?
Expiration in 2030 means exclusivity ends around 2030, emphasizing the need for timely market entry, licensing deals, or additional patent filings.
5. How does regulatory data exclusivity impact this patent?
Data exclusivity rights can delay generic entry beyond patent expiry if granted, adding effective market protection.
References
[1] Taiwan Patent Office. (2010). Patent registration details for TW201018688.
[2] Patent Cooperation Treaty. (2019). Overview of international patent prosecution.
[3] World Intellectual Property Organization. (2022). Patent landscape reports and strategies.
[4] Taiwan Patent Act (2014). Laws governing patent rights and enforcement.
[5] European Patent Office. (2020). Patent claim drafting and scope analysis.
